Evonik invests in methionine production for dairy cows
• Company to construct a plant to produce Mepron® inMobile (Alabama, USA)
• Additional growth opportunities for the global amino acidbusiness seen
• Says Executive Board member Patrik Wohlhauser, "Thisinvestment strengthens our position as the world's leading
supplier of amino acids."

August 12, 2014
Contact person economic press
Silke Linneweber
Corporate Press
Phone +49 201 177-3389
Fax +49 201 177-3030
silke.linneweber@evonik.com
Contact person specialized press
Dr. Jürgen Krauter
Communication Health & Nutrition
Phone +49 6181 59-6847Fax +49 6181 59-76847
juergen.krauter@evonik.com

Essen/Mobile. Evonik Industries has begun construction of a newplant to produce Mepron® in Mobile (Alabama, USA). Mepron® is a
special Evonik formulation of the amino acid methionine that isused in dairy cow nutrition. A special coating protects the aminoacid from undesired degradation in the rumen. The new plant isscheduled for completion in the second half of 2015. The
investment is in the low double-digit-million-euro range.
Evonik Executive Board member and Chief Operating Officer Patrik
Wohlhauser explains, "The investment strengthens our position as
the world's leading supplier of amino acids. We continue ourstrategy of offering amino acids also for special applications inaddition to MetAMINO®, which is used mainly in poultry and pig
feed. This opens up new growth opportunities for our amino acidbusiness.""The new plant for Mepron® will give us a direct presence in theimportant US dairy cow market," says Dr. Reiner Beste, Head of
Evonik's Health & Nutrition Business Unit. The USA, which has theworld's largest number of high yielding dairy cows, is the mostimportant sales region for Mepron®. A similar potential exists inthe European Union. The United States are responsible for about
12.5 percent of the global milk production.
Mepron® improves profitability of milk production
When Mepron® is used in dairy cow rations, farmers can reduce theamount of crude protein in the feed with no adverse effect onperformance. This lowers the total feed costs for the producer andincreases the profitability of dairy cow farming.
Page 1 of 2

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.de
Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Christian Kullmann
Thomas Wessel
Patrik Wohlhauser
Ute Wolf
Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003

Methionine is one of the essential amino acids that higherorganisms need to ingest. If dairy cows lack methionine, theycannot utilize their feed protein properly. The main application for
Mepron® is feed for high yielding dairy cows. These animals havean especially high demand for methionine, which is provided inconventional rations through high amounts of protein in the feed.
The number of high yielding dairy cows is increasing throughout
the world. One of the reasons for this is the improvement of theefficiency of farming.
In addition, the environmentally compatible production ofagricultural products conserving resources is becoming more
important for ecological reasons. Feed rations that are optimizedon the basis of amino acids relieve the animal's metabolism and —because of the lower nitrogen excretion — also the environment.
Evonik is the only company in the world that produces and markets
the four most important amino acids that are required in advanced
animal feed: MetAMINO® (DL-methionine), Mepron® (DLmethionine for ruminants), DL-Methionine for Aquaculture®,
Biolys® (L-lysine source), ThreAMINO® (L-threonine), andTrypAMINO® (L-tryptophan). As a solution provider, the Group also
supports its customers with comprehensive professional advice,tailored services, and a worldwide sales organization for all aminoacid products.
About Evonik
Evonik, the creative industrial group from Germany, is one of the world leaders inspecialty chemicals. Profitable growth and a sustained increase in the value of thecompany form the heart of Evonik’s corporate strategy. Its activities focus on thekey megatrends health, nutrition, resource efficiency and globalization. Evonik
benefits specifically from its innovative prowess and integrated technology
platforms.
Evonik is active in over 100 countries around the world. In fiscal 2013 more than
33,500 employees generated sales of around €12.7 billion and an operating profit(adjusted EBITDA) of about €2.0 billion.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where
our statements concern the future, these forecasts, expectations or statements
may involve known or unknown risks and uncertainties. Actual results ordevelopments may vary, depending on changes in the operating environment.
Neither Evonik Industries AG nor its group companies assume an obligation toupdate the forecasts, expectations or statements contained in this release.

Page 2 of 2